Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4

Imagem de Miniatura
Arquivos
art_BETONICO_Insulin_Glargine_U100_Improved_Glycemic_Control_and_Reduced_2019.PDF (1.02 MB)
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
Citação
CLINICAL THERAPEUTICS, v.41, n.10, p.2008-2020, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: Glycemic control in patients with chronic kidney disease (CKD) is particularly hard to achieve because of a slower insulin degradation by the kidney. It might modify the long-acting insulin analogue pharmacokinetics, increasing its time-action and the risk of hypoglycemia. However, because this insulin has no peak action, it might be a more tolerable approach to patients with CKD. This hypothesis remains to be tested, because no study has thus far examined the efficacy and safety profile of long-acting basal analogues in patients with significant loss of renal function. The purpose of this study was to compare the glycemic response to treatment with glargine U100 or neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes mellitus (T2DM) and CKD stages 3 and 4. Methods: Thirty-four patients were randomly assigned to glargine U100 or NPH insulin after a 2-way crossover open-label design. The primary end point was the difference in glycosylated hemoglobin (HbA(1c)) and in the number of hypoglycemic events between weeks 1 and 24, whereas secondary end points included changes in glycemic patterns, weight and body mass index, and total daily dose of insulin. HbA(1)(c) was determined by ion-exchange HPLC, and hypoglycemia was defined as glucose concentration of 54 mg/dL (3.0 mmol/L) detected by self-monitoring of plasma glucose or continuous glucose monitoring. Findings: After 24 weeks, mean HbA(1c )decreased on glargine U100 treatment (-0.91%; P < 0.001), but this benefit was not observed for NPH (0.23%; P = 0.93). Moreover, incidence of nocturnal hypoglycemia was 3 times lower with glargine than with NPH insulin (P = 0.047). (C) 2019 Published by Elsevier Inc.
Palavras-chave
basal insulin analogue, chronic kidney disease, hypoglycemia, insulin therapy, type 2 diabetes mellitus
URI
https://observatorio.fm.usp.br/handle/OPI/34292
Referências
  1. ADROGUE HJ, 1992, KIDNEY INT, V42, P1266, DOI 10.1038/ki.1992.414
  2. Alsahli M, 2015, J CLIN MED, V4, P948, DOI 10.3390/jcm4050948
  3. American Diabetes Association, 2004, DIABETES CARE, V27, P579
  4. Amiel SA, 2017, DIABETES CARE, V40, P155, DOI 10.2337/dc16-2215
  5. Bazzano LA, 2008, DIABETIC MED, V25, P924, DOI 10.1111/j.1464-5491.2008.02517.x
  6. Brady VJ, 2017, NURS CLIN N AM, V52, P539, DOI 10.1016/j.cnur.2017.07.004
  7. Cersosimo E, 1999, DIABETES, V48, P261, DOI 10.2337/diabetes.48.2.261
  8. Cha SA, 2016, DIABETES METAB J, V40, P202, DOI 10.4093/dmj.2016.40.3.202
  9. Cupp M., 2009, PHARM LETT, V25
  10. Davies M, 2016, CLIN PHARMACOL-ADV A, V8, P61, DOI 10.2147/CPAA.S82008
  11. Dluhy RG, 2008, NEW ENGL J MED, V358, P2630, DOI 10.1056/NEJMe0804182
  12. Fliser D, 1998, KIDNEY INT, V53, P1343, DOI 10.1046/j.1523-1755.1998.00898.x
  13. Gabriely I, 2004, CLEV CLIN J MED, V71, P335, DOI 10.3949/ccjm.71.4.335
  14. de Lucas MDG, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13098
  15. George CM, 2018, AM J MED, V131, P752, DOI 10.1016/j.amjmed.2018.01.049
  16. HAGER SR, 1989, AM J KIDNEY DIS, V14, P272, DOI 10.1016/S0272-6386(89)80201-X
  17. Hanefeld M, 2016, DIABETES CARE, V39, pS205, DOI 10.2337/dcS15-3014
  18. Hedrington MS, 2011, DIABETES TECHNOL THE, V13, DOI 10.1089/dia.2011.0062
  19. Heise Tim, 2018, J Diabetes Sci Technol, V12, P356, DOI 10.1177/1932296817731422
  20. Horita S, 2016, BIOMED RES INT, DOI 10.1155/2016/5825170
  21. Lipska KJ, 2018, JAMA-J AM MED ASSOC, V320, P53, DOI 10.1001/jama.2018.7993
  22. MAK RHK, 1992, NEPHRON, V61, P377, DOI 10.1159/000186953
  23. Matthews DR, 1998, DIABETIC MED, V15, P297, DOI 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.3.CO;2-N
  24. Mauricio Didac, 2018, Eur Endocrinol, V14, P2, DOI 10.17925/EE.2018.14supp1.2
  25. Moen MF, 2009, CLIN J AM SOC NEPHRO, V4, P1121, DOI 10.2215/CJN.00800209
  26. Monnier L, 2011, DIABETES TECHNOL THE, V13, P813, DOI 10.1089/dia.2011.0049
  27. Niafar M, 2012, J DIABETES METAB, V3, DOI 10.4172/2155-6156.1000189
  28. Pandya N, 2013, DRUG AGING, V30, P429, DOI 10.1007/s40266-013-0069-9
  29. Papademetriou V, 2015, KIDNEY INT, V87, P649, DOI 10.1038/ki.2014.296
  30. Pecoits R, 2016, DIABETOL METAB SYNDR, V8, DOI 10.1186/s13098-016-0159-z
  31. Pfeiffer C, 2003, DIABETIC MED, V20, P545
  32. Pieber TR, 2018, DIABETOLOGIA, V61, P58, DOI 10.1007/s00125-017-4422-0
  33. RABKIN R, 1984, DIABETOLOGIA, V27, P351, DOI 10.1007/BF00304849
  34. Ramlo-Halsted BA, 1999, PRIMARY CARE, V26, P771, DOI 10.1016/S0095-4543(05)70130-5
  35. Riebenfeld D, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14114
  36. Rys P, 2015, ACTA DIABETOL, V52, P649, DOI 10.1007/s00592-014-0698-4
  37. Sampanis C, 2008, HIPPOKRATIA, V12, P22
  38. Speeckaert M, 2014, NEPHROL DIAL TRANSPL, V29, P2167, DOI 10.1093/ndt/gfu006
  39. Wang F, 2003, CLIN THER, V25, P1541, DOI 10.1016/S0149-2918(03)80156-X
  40. Yale JF, 2017, CAN J DIABETES, V41, P478, DOI 10.1016/j.jcjd.2017.06.007

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - ODS/03